(Total Views: 1027)
Posted On: 01/08/2020 11:06:42 PM
Post# of 148903
From Cydy website presentation.
mTNBC
• Phase 1b/2 initiated – unmet medical need
• Granted Fast-Track designation by FDA based on a greater than 98%
reduction of metastatic tumor volume in a murine xenograft model
• Sept 2019 – Four patients injected
• Based on current results, we will file Breakthrough Therapy Designation in
January 2020
mTNBC
• Phase 1b/2 initiated – unmet medical need
• Granted Fast-Track designation by FDA based on a greater than 98%
reduction of metastatic tumor volume in a murine xenograft model
• Sept 2019 – Four patients injected
• Based on current results, we will file Breakthrough Therapy Designation in
January 2020
(0)
(0)Scroll down for more posts ▼
